Company intelligence / Profile preview
Zhifei Biological
- Ownership
- Private
- Employees
- ~7365
- Development stage
- Other
Overview
Zhifei Biological has over a dozen commercialized vaccines covering major infectious diseases including COVID-19 and meningitis. Its pipeline features next-generation pneumococcal vaccines in late-stage development and innovative candidates such as a Shigella bivalent vaccine in Phase 3 trials. The company leverages multiple proprietary platforms for rapid R&D of new vaccines
- Therapeutic areas
- Infectious Diseases
- Modalities
- VaccineRecombinant proteinPolysaccharide and conjugate vaccinemRNA-based drugs
- Industry
- Biotech
Drug pipeline
30 assets29 more assets in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on Zhifei Biological.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zhifei Biological.